Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study...
-
GoGuardian Beacon's Active Planning Alerts achieves international certification for AI governance
-
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026Consistent, convergent improvements...
-
“America's Got Talent” Choir to Perform at Canadian Anti-Racism and Youth Mental Health Conference
-
InStride reports 97% patient improvement in 2026, doubling enrollment and expanding across 5 East Coast markets while maintaining strong clinical results.
-
Mental Health Awareness Month highlights declining well-being as Americans turn to self-help resources for solutions.
-
New York, May 05, 2026 (GLOBE NEWSWIRE) -- We know that positive emotions motivate us to pursue important goals, savor experiences, counteract the cardiovascular effects of stress, and maintain...
-
WellWithAll launched the WellWithAll HBCU Pour Back Series, a long-term, multi-year commitment to invest in HBCU as critical engines of health & wellbeing.
-
neurocare group AG receives SFDA MDMA approval for TMS devices in Saudi Arabia, enabling access to non‑invasive, evidence‑based mental health treatment.
-
neurocare group AG receives SFDA MDMA approval for TMS devices in Saudi Arabia, enabling access to non‑invasive, evidence‑based mental health treatment.